11/18
02:03 am
bcrx
BioCryst Launches ORLADEYO® (berotralstat) in Ireland [Yahoo! Finance]
Low
Report
BioCryst Launches ORLADEYO® (berotralstat) in Ireland [Yahoo! Finance]
11/18
02:00 am
bcrx
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
Low
Report
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
11/6
07:00 am
bcrx
BioCryst to Present at Upcoming Investor Conferences
Medium
Report
BioCryst to Present at Upcoming Investor Conferences
11/5
11:19 am
bcrx
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Low
Report
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
11/5
10:41 am
bcrx
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Low
Report
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
11/5
09:43 am
bcrx
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Barclays PLC from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
Low
Report
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at Barclays PLC from $7.00 to $8.00. They now have an "equal weight" rating on the stock.
11/5
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/5
05:35 am
bcrx
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/5
02:14 am
bcrx
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... [Yahoo! Finance]
Medium
Report
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... [Yahoo! Finance]
11/4
02:41 pm
bcrx
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/4
07:05 am
bcrx
BioCryst Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $0.01, revenue of $117.09M beats by $3.09M [Seeking Alpha]
Medium
Report
BioCryst Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $0.01, revenue of $117.09M beats by $3.09M [Seeking Alpha]
11/4
07:00 am
bcrx
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
10/24
08:00 am
bcrx
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
Low
Report
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
10/21
07:00 am
bcrx
BioCryst to Report Third Quarter 2024 Financial Results on November 4
Low
Report
BioCryst to Report Third Quarter 2024 Financial Results on November 4
10/14
07:00 am
bcrx
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
Low
Report
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
10/10
07:00 am
bcrx
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
Low
Report
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
10/7
02:06 pm
bcrx
BioCryst (BCRX) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
BioCryst (BCRX) Upgraded to Buy: Here's Why [Yahoo! Finance]
10/3
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/2
07:00 am
bcrx
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
Low
Report
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
9/30
10:41 am
bcrx
With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns [Yahoo! Finance]
9/30
07:00 am
bcrx
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
Low
Report
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
9/17
07:09 am
bcrx
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks [Financial Post (Toronto, Ontario, Canada)]
Low
Report
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks [Financial Post (Toronto, Ontario, Canada)]
9/17
07:00 am
bcrx
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
Low
Report
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
9/6
02:24 am
bcrx
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium [Yahoo! Finance]
Low
Report
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium [Yahoo! Finance]
9/6
02:00 am
bcrx
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
Low
Report
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium